Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TRTP-101

PreclinicalCell therapy

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atrophic ScarRecruiting

Atrophic ScarPreclinical

Recruiting

Timeline

Expected Milestones

Q3 2029

PreclinicalRecruiting

Atrophic Scar

NCT07474467

Clinical

Trials by Indication[1]

Mesenchymal Stem Cells1 trial

Safety and Tolerability of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars

Completed·CCellinCells·Phase 1·NCT06210919·3 enrolled

Atrophic Scar1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Split-Face, Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Administration of TRTP-101 in Adults With Atrophic Scars

Recruiting·CCellinCells·Preclinical·NCT07474467·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TRTP-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TRTP-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TRTP-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CellinCells company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: CCellinCells

Related News